PMID- 20079327
OWN - NLM
STAT- MEDLINE
DCOM- 20160423
LR  - 20181217
IS  - 0578-1426 (Print)
IS  - 0578-1426 (Linking)
VI  - 48
IP  - 11
DP  - 2009 Nov
TI  - [Insulin resistance and islet beta cell function in type 2 diabetes mellitus and 
      non alcoholic fatty liver disease.].
PG  - 940-3
AB  - OBJECTIVE: To investigate insulin resistance and islet beta cell function in type 
      2 diabetes mellitus (T2DM) and non alcoholic fatty liver disease (NAFLD). 
      METHODS: Two hundred and six study subjects were classified into 4 groups. 
      Hepatic insulin resistance index (HIR), HOMA insulin resistance index (HOMA-IR) 
      and Matsuda index (MSI) were used to assess insulin resistance. HOMA-beta, early 
      and late phase indexes of insulin secretion were used to evaluate islet beta cell 
      function. RESULTS: HIR in the NAFLD group and T2DM with NAFLD group were 
      significantly higher than that in the control group and T2DM group (4.13 +/- 
      0.64, 4.03 +/- 0.69 vs 3.52 +/- 0.78, 3.53 +/- 0.64, P < 0.05), HOMA-IR in the 
      T2DM with NAFLD group was significantly higher than that in the NAFLD group and 
      T2DM group (3.35 +/- 2.69 vs 2.31 +/- 1.39, 2.40 +/- 1.55, P < 0.05). Early phase 
      insulin secretion index in the NAFLD group was lower than that in the control 
      group significantly (2.13 +/- 0.17 vs 2.61 +/- 0.13, P < 0.05), but there was no 
      significant difference of HOMA-beta and late phase insulin secretion index 
      between the NAFLD group and control group, HOMA-beta, early and late phase 
      indexes of insulin secretion in the T2DM group and T2DM with NAFLD group were 
      significantly lower than those in the control group. CONCLUSIONS: Normal glucose 
      tolerance NAFLD patients may present with insulin resistance, mainly hepatic 
      insulin resistance. Islet beta cell function in the NAFLD patients show damage of 
      early phase insulin secretion. Newly diagnosed T2DM with or without NAFLD 
      patients generally present with insulin resistance, early and later phase insulin 
      secretion dysfunction. Insulin resistance in patients with T2DM and NAFLD is more 
      severe.
FAU - Li, Fang-Ping
AU  - Li FP
AD  - Department of Endocrinology and Metabolism, The Second Affiliated Hospital, Sun 
      Yat-sen University, Guangzhou 510120, China. Email: Amiy36@hotmail.com.
FAU - Zhang, Si-Qing
AU  - Zhang SQ
FAU - Wang, Fei
AU  - Wang F
FAU - Huang, Yin-Qiong
AU  - Huang YQ
FAU - Fu, Zu-Zhi
AU  - Fu ZZ
FAU - Yan, Li
AU  - Yan L
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhonghua Nei Ke Za Zhi
JT  - Zhonghua nei ke za zhi
JID - 16210490R
RN  - 0 (Insulin)
SB  - IM
MH  - *Diabetes Mellitus, Type 2/metabolism
MH  - Humans
MH  - Insulin/metabolism
MH  - *Insulin Resistance
MH  - Insulin Secretion
MH  - Insulin-Secreting Cells/metabolism
MH  - Non-alcoholic Fatty Liver Disease/metabolism
EDAT- 2010/01/19 06:00
MHDA- 2016/04/24 06:00
CRDT- 2010/01/19 06:00
PHST- 2010/01/19 06:00 [entrez]
PHST- 2010/01/19 06:00 [pubmed]
PHST- 2016/04/24 06:00 [medline]
PST - ppublish
SO  - Zhonghua Nei Ke Za Zhi. 2009 Nov;48(11):940-3.